Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Lung Cancer

Journal Scan / Research · May 11, 2021

Effect of Trilaciclib on Chemo-Induced Myelosuppression in Extensive-Stage SCLC

Clinical Lung Cancer


Additional Info

Clinical Lung Cancer
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
Clin Lung Cancer 2021 Mar 26;[EPub Ahead of Print], J Weiss, J Goldschmidt, Z Andric, KH Dragnev, C Gwaltney, K Skaltsa, Y Pritchett, JM Antal, SR Morris, D Daniel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading